FR2583640A1 - Pharmaceutical compositions for vasculotropic and antisclerotic use - Google Patents

Pharmaceutical compositions for vasculotropic and antisclerotic use Download PDF

Info

Publication number
FR2583640A1
FR2583640A1 FR8509566A FR8509566A FR2583640A1 FR 2583640 A1 FR2583640 A1 FR 2583640A1 FR 8509566 A FR8509566 A FR 8509566A FR 8509566 A FR8509566 A FR 8509566A FR 2583640 A1 FR2583640 A1 FR 2583640A1
Authority
FR
France
Prior art keywords
extracts
salts
extract
ginseng
eleutherococcus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR8509566A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR8509566A priority Critical patent/FR2583640A1/en
Publication of FR2583640A1 publication Critical patent/FR2583640A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The innovation application relates to the pharmaceutical compositions defined by the combination of at least two constituents chosen from a different group from the following groups: the group comprising vasodilators and (or) vasculoprotectants and the group comprising general and/or cerebral stimulants.

Description

DESCRIPTION
La présente demande d'innovation concerne l'association synergique,en vue de l'obtention d'un effet de relance et(ou) un effet protecteur sur le métabolisme des cellules,d'au moins deux constituants choisis dans un groupe différent parmi les groupes suivants: -le groupe des vasodilatateurs et (ou) des vasculoprotecteurs -le groupe des stimulants généraux et et(ou) cérébraux.DESCRIPTION
The present innovation request relates to the synergistic association, with a view to obtaining a stimulating effect and / or a protective effect on the metabolism of cells, of at least two constituents chosen from a different group among the following groups: -the group of vasodilators and / or vasculoprotectors -the group of general and and / or cerebral stimulants.

Ainsi cette association permet d'agir sur les deux aspects de l'ischémie tissulaire:
-d'une part grâce au(x) vasodilatateur(s) et (ou) vasculopro
tecteur(s)d'améliorer les conditions hémodynamiques au niveau
du tissu
-d'autre part grâce au(x) stimulant(s) génèral(aux) et (ou) ce're'bral(aux) d'augmenter les capacités d'assimilation des
nutriments au niveau de la cellule.Thus this association makes it possible to act on the two aspects of tissue ischemia:
- on the one hand thanks to the vasodilator (s) and (or) vasculopro
guardian (s) to improve hemodynamic conditions at the
fabric
-on the other hand thanks to (x) general stimulant (s) and / or (cerebral) to increase the assimilation capacities of
nutrients at the cell level.

Toutes les substances ayant des propriérés vasodilatatrices et(ou) vasculoprotectrices et(ou) analeptiques connues de l'homme de l'art peuvent être utilisées.les quelques exemples non exhaustif s cités ci-après ne sont donnés qu'à titre d'exemples non limitatifs:
Exemple I: extrait hydrosoluble(par exemple:extrit fluide et (ou) extrait hydroalcoolique et (ou) nébulisat)de ginko
biloba et (ou) de vinca minor et (ou) de ruscus aculeatus et (ou) de vitis vinifera et (ou) d' aesculus hippocastanum que l'on associera eventuellement aux produits suivants: ia(les)vitamine(s) A,C,D,D2,D3,E,pP,BI,B2,B3,B4,B5,B6,B7,BS, B9,BT,BI2,BI5,F,G,H,H2,K,KI,K3,LI(acide orthobenzoïque),M, d'une part: extrait hydrosoluble(par exemple:extrait fluide et(ou) extrait hydroalcoolique et (ou) nébulisat) de ginseng et (ou) d'éleuthérococcus, et (ou) inositol, et (ou) lécithine, et (ou) déanol,et(ou) bétaïne,et(ou) oligoélément(s),et(ou) protéoly- sat, et (ou) plasmolysat,et(ou) acide(s) aminé(s),et(ou) enzyme (s); d'autre part.All substances having vasodilator and / or vasculoprotective and / or analeptic properties known to a person skilled in the art can be used. The few non-exhaustive examples cited below are given only by way of examples non-limiting:
Example I: water-soluble extract (for example: fluid extract and / or hydroalcoholic extract and (or) nebulizer) of ginko
biloba and / or vinca minor and / or ruscus aculeatus and / or vitis vinifera and / or aesculus hippocastanum which may be combined with the following products: ia (the) vitamin (s) A, C, D, D2, D3, E, pP, BI, B2, B3, B4, B5, B6, B7, BS, B9, BT, BI2, BI5, F, G, H, H2, K, KI, K3, LI (orthobenzoic acid), M, on the one hand: water-soluble extract (for example: fluid extract and (or) hydroalcoholic extract and (or) nebulizer) of ginseng and (or) eleutherococcus, and (or) inositol, and (or) lecithin, and (or) deanol, and (or) betaine, and (or) trace element (s), and (or) proteolysat, and (or) plasmolysate, and (or) amino acid (s) ( s), and (or) enzyme (s); on the other hand.

Exemple 2: ginko biloba extrait fluide et (ou) nébulisat
ginseng (racine rouge) extrait fluide et (ou) nébulisat
ascorbate de sodium et (ou) acide ascorbique

Figure img00020001
Example 2: ginko biloba fluid extract and (or) nebulizer
ginseng (red root) fluid extract and / or nebuliser
sodium ascorbate and / or ascorbic acid
Figure img00020001

Exemple 3: ( nébulisat de la racine rouge semi-sauvage et(ou) sauvage ( du ginseng de chine:200 mg nébulisant des feuilles du ginko biloba:200mg vitamine C:IOO mg qsp une gélule:une ou deux gélules deux ou trois fois par jour. Example 3: (nebulisate of the semi-wild and / or wild red root (of Chinese ginseng: 200 mg nebuliser of the leaves of ginko biloba: 200 mg vitamin C: IOO mg qsp one capsule: one or two capsules two or three times per day.

Exemple 4: ( nébulisat de la racine d'éleuthérococcus senticoccus max:. Example 4: (nebulized root of eleutherococcus senticoccus max :.

i25 mg ( nébulisat le la racine rouge semi-sauvage du ginseng de chine:
i25 mg ( nébulisat des feuilles du ginko biloba:200 mg ( vitamine C:50mg qsp une gélule:une à six gélules par jour
Les formes de présentation,les voies d'introduction,les doses et les posologies ne sont données qu'à titre d'exemple non limitatif.De même les substances d'origine naturelle peuvent être présentées sous norme du(des)principes(s) actif(s). i25 mg (nebulized the semi-wild red root of Chinese ginseng:
i25 mg (nebulized ginko biloba leaves: 200 mg (vitamin C: 50 mg qs one capsule: one to six capsules per day
The forms of presentation, the routes of introduction, the doses and the dosages are given only by way of nonlimiting example. Likewise substances of natural origin can be presented under standard of the principle (s) active.

Quant aux extraits:tous les types d'extrait connus del'homme de l'art peuvent être utilisés(à titre d'exemple:les extraits fluides ou liquides, les extraits secs,les extraits dits mous ou fermes à consistance intermédiaire plus ou moins épaisse, les nébulisats,les extraits hydroalcooliques,les extraits hydroalcooloéthériques,les extraits éthériques,les suspensions,etc...)
Les différentes variétés du ginseng peuvent être utilisées(le Panax Ginseng Mey,le Panax (Aralia) quinquefolium L,le Sium Ninzi
Lour,le Ginseng chinois). As for extracts: all types of extract known to those skilled in the art can be used (for example: fluid or liquid extracts, dry extracts, so-called soft or firm extracts of more or less intermediate consistency thick, nebulisates, hydroalcoholic extracts, hydroalcoholic ethereal extracts, etheric extracts, suspensions, etc.)
The different varieties of ginseng can be used (Panax Ginseng Mey, Panax (Aralia) quinquefolium L, Sium Ninzi
Lour, Chinese Ginseng).

Claims (8)

REVENDICATION CLAIM I-Les produits caractérisés en ce qu'ils sont constitués par une association d'au moins deux constituants choisis dans un groupe différent parmi les groupes suivants: le groupe des vasodilatateurs et (ou) des vasculoprotecteurs; le groupe des stimulants généraux et (ou) cérébraux. I-The products characterized in that they consist of a combination of at least two constituents chosen from a different group from the following groups: the group of vasodilators and (or) vasculoprotectors; the group of general and / or brain stimulants. 2-Médicament selon la revendication I,caractérisé en ce qu'il contient du ginko biloba et du ginseng et(ou) de 1' éleuthérococcus (à titre d'exemple non limitatif:panax ginseng mey ,ginseng de chine, racine rouge de ginseng de chine,éleuthérococcus senticoccus max,racine d'éleuthérococcus senticoccus max,ginko biloba plante entière et (ou) racine et (ou) feuille) :ces produits pouvant être présentés sous toutes les formes possibles connues de l'homme de l'art (telles qui à titre d' exemple non limitatif::la forme pure et (ou) la forme d'extrait (s) et(ou) la forme du(des) principes) actif(s) (tel qu'à titre d'exemple non limitatif les hétérosides,les glucosides ,les saponosides,panaxadiol,panaxatriol, éleuthéroside A,B, BI,C,D,E,I,K,L,M,hétérosides et (ou) glucosides du ginko biloba ,etc...)scus la forme par exemple de poudre,d'extrait sec d'extrait fluide,de nébulisat ,extrait hydroalcoolique,extrait concentré,titré en principes actifs,extrait liposoluble-(par exemple les huiles essentielle; association de plusieurs types d'extraits,ou toutes autres formes connues de l'homme de 1' art particulièrement dans l'art de la phyto-galénique ou galénique phytothérapeutique. 2-medicament according to claim I, characterized in that it contains ginko biloba and ginseng and (or) 1 eleutherococcus (by way of nonlimiting example: panax ginseng mey, Chinese ginseng, red ginseng root from China, eleutherococcus senticoccus max, eleutherococcus senticoccus max root, ginko biloba whole plant and / or root and / or leaf): these products can be presented in all the possible forms known to those skilled in the art ( such which by way of nonlimiting example: the pure form and / or the form of extract (s) and (or) the form of the active ingredient (s) (such as nonlimiting example the heterosides, the glucosides, the saponosides, panaxadiol, panaxatriol, eleutheroside A, B, BI, C, D, E, I, K, L, M, heterosides and (or) glucosides of ginko biloba, etc. .) scus the form for example of powder, dry extract of fluid extract, nebuliser, hydroalcoholic extract, concentrated extract, titrated in active principles, fat-soluble extract- (for example esse oils ntielle; association of several types of extracts, or any other form known to those skilled in the art, particularly in the art of phyto-galenic or galenic phytotherapeutic. 3-Médicament selon la revendication I,caractérisé en ce qu'il contient en tant qu'agent vasodilatateur et (ou) vasculoprotecteur au moins l'un des constituants suivants:acide nicotinique,nicotinates,papavérine et (ou) ses sels, procaine et(ou) ses sels,dihydroergotoxine et (ou) ses sels(tel que par exemple le méthane sulfonate),dihydroergocornine et(ou) ses sels,dihydroergocristine et (ou) ses sels,dihydroergocryptine et (ou) ses sels,spartéine et (ou) ses sels,kalléine,choline et (ou) ses sels,citrate de choline,acide citrique,vincamine et (ou) ses sels, fraction vincique,raubasine et (ou) ses sels,rutine,rutoside(s) et (ou) ses sels, ruscogènine (s), inosi- tol,étamiphylline,pentaméthonium et (ou) ses sels,naftidro- furyl et (ou) ses sels, troxerutine,butoforme,théophylline et (ou) ses dérivés,escine,aesculoside(s),anthocyanoside(s), catéchine(s),leucoanthocyane(s),flavono^ide(s),cltroflavonoï- defs),hespéridine et(ou) ses sels (par exemple:hesperidine méthylchalcone),methesculétol,héparine,iodohéparine,hydroxy- flavonines, leucocianidol, acide flavodique,coumarine(s),ruscus tel que par exemple:ruscus aculeatus et(ou): leur(s) extrait(s),aesculus tel que par exemple:aesculus hippocastanum et(ou) leur(s) extrait(s),hamamelis et(ou) ses extraits, ribes nigrum et (ou) ses extraits,vaccinum vitis ideae et et(ou) ses extraits,cupressustel que par exemple cupressus sempervi rens et ses extraits,vitis vinifera et ses extraits,vinca minor et aes extraits,vaccinum myrtillus et ses extraits et (ou) toute autre substance connue de l'homme de l'art comme présentant des propriétés vasodilatatrices et (ou) vasculotropes,que cette (ces) substance(s) soit(soient) d'origine végétale,animale,minérale,synthéthique,hémisynthétique et (ou) tirée de microorganisme.  3-medicament according to claim I, characterized in that it contains as vasodilator and / or vasculoprotective agent at least one of the following constituents: nicotinic acid, nicotinates, papaverine and (or) its salts, procaine and (or) its salts, dihydroergotoxin and (or) its salts (such as for example methane sulfonate), dihydroergocornine and (or) its salts, dihydroergocristine and (or) its salts, dihydroergocryptine and (or) its salts, sparteine and ( or) its salts, kaleine, choline and / or its salts, choline citrate, citric acid, vincamine and / or its salts, vincic fraction, raubasine and (or) its salts, rutin, rutoside (s) and (or ) its salts, ruscogenin (s), inositol, etamiphylline, pentamethonium and (or) its salts, naftidro-furyl and (or) its salts, troxerutin, butoform, theophylline and (or) its derivatives, escin, aesculoside (s ), anthocyanoside (s), catechin (s), leucoanthocyane (s), flavonoid (s), cltroflavonoid- defs), hesperidin and (or) its salts (for example: hesperidine methylchalcone), methesculeto l, heparin, iodoheparin, hydroxy-flavonins, leucocianidol, flavodic acid, coumarin (s), ruscus such as for example: ruscus aculeatus and (or): their extract (s), aesculus such as for example: aesculus hippocastanum and (or) their extract (s), hamamelis and / or its extracts, ribes nigrum and (or) its extracts, vaccinum vitis ideae and and (or) its extracts, cupressustel as for example cupressus sempervi rens and its extracts, vitis vinifera and its extracts, vinca minor and its extracts, vaccinum myrtillus and its extracts and / or any other substance known to those skilled in the art as having vasodilator and / or vasculotropic properties, other than this (these ) substance (s) either (of) vegetable, animal, mineral, synthetic, semi-synthetic and (or) originated from microorganisms. 4-Médicament selon la revendication I,caractérisé en ce qu'il contient en tant que stimulant général et (ou) cérébral au moins l'un des constituants suivants: ginseng et ses extraits ,éleuthérococcus et ses extraits, l'inositol,la lécithine,le déanol,.la bétaïne,.. les oligoéléments,les acides aminés, les enzymes,les cardioanalep- tiques, les analeptiques cérébraux tels que par exemple les amphétaminiques,les anoréxygènes,ainsi que toutes substances connues be l'homme de l'art pour avoir une action stimulante sur le métabolisme des cellules. 4-Medicament according to claim I, characterized in that it contains as general and / or cerebral stimulant at least one of the following constituents: ginseng and its extracts, eleutherococcus and its extracts, inositol, lecithin , deanol,. betaine, .. trace elements, amino acids, enzymes, cardioanaleptics, cerebral analeptics such as for example amphetamines, anorexygens, as well as all substances known to man art to have a stimulating action on the metabolism of cells. 5-Médicament selon la revendication I,caractérisé en ce qu'il contient d'une part:du ginseng et (ou) ses extraits,et(ou) de l'éleuthérococcus et (ou) ses extnaits,et(ou) de l'inositol, et (ou) de la lécithine,et(ou) du déanol,et(ou) de la bétoine, et (ou) des oligoélèments,et(ou) des protéolysat, et (ou) des plasmolysats,et (ou) des acides aminés,et(ou) des enzymes; et d'autre part du ginko biloba et (ou) ses extraits,et(ou) du vinca minor et (ou) ses extraits,et(ou) du ruscus aculeatus et(ou) ses extraits,et(ou) de l'aesculus hippocastanum et (ou) ses extraits,et(ou) du vitis viniféra et (ou) ses extraits, et(ou) de l'hamamélis et (ou) ses extraits,et(ou) de llhydroergo -toxine et (ou) ses extraits,éventuellement associé(s) à la (les) vitamine(s) A, C, D, D2,D3, E, PP, BI,B2,B3,B4,B5,B6,B7,BS,B9, BT,BI2,BT5,F,G,H,H2,KI,K3,LI(acide orthobenzoïque),M,et(ou) à la choline. 5-medicament according to claim I, characterized in that it contains on the one hand: ginseng and (or) its extracts, and (or) eleutherococcus and (or) its extnaits, and (or) l inositol, and (or) lecithin, and (or) deanol, and (or) betony, and (or) trace elements, and (or) proteolysate, and (or) plasmolysates, and (or ) amino acids, and (or) enzymes; and on the other hand ginko biloba and / or its extracts, and / or vinca minor and / or its extracts, and / or ruscus aculeatus and / or its extracts and / or aesculus hippocastanum and / or its extracts, and / or vitis viniféra and / or its extracts, and / or witch hazel and / or its extracts, and / or llhydroergo -toxin and / or its extracts, possibly associated with vitamin (s) A, C, D, D2, D3, E, PP, BI, B2, B3, B4, B5, B6, B7, BS, B9, BT , BI2, BT5, F, G, H, H2, KI, K3, LI (orthobenzoic acid), M, and (or) with choline. 6-Médicament selon la revendication I,caractérisé en ce qu'il conticnt d'une part:du ginseng et (ou) ses extraits, et (ou) de l'éleuthérococcus et (ou) ses extraits, et d'autre part du ginko biloba et (ou) ses extraits,et(ou) de la papavérine et (ou) ses sels, et (ou) de la vincamine et (ou) ses sels, et (ou) du vinca minor et(ou)ses extraits,et(ou) de la rutine et(ou) des rutosides et (ou) de leurs sels(rutine et rutosides se présentant sous forme du(des) principe(s) actif(s) et (ou) sous forme d'extrait naturel concentré),et(our des flavonoides et (ou) de leurs sels,et (ou) des hesperidines et (ou) de leurs sels,et(ou) de la raubasine et (ou) de ses sels,et(ou) de la troxérutine et (ou) de ses sels (raubasine et troxérutine se présente -ront sous la forme des principes actifs et (ou) des extraits naturels concentrés comme il en est de toutes les substances d'origine naturelle décrites dans l'une quelconque des revendications). 6-medicament according to claim I, characterized in that it contains on the one hand: ginseng and (or) its extracts, and (or) eleutherococcus and (or) its extracts, and on the other hand ginko biloba and / or its extracts, and / or papaverine and / or its salts, and / or vincamine and / or its salts, and / or vinca minor and / or its extracts , and (or) rutin and (or) rutosides and / or their salts (rutin and rutosides in the form of the active principle (s) and (or) in the form of an extract concentrated natural), and (for flavonoids and / or their salts, and (or) hesperidines and (or) their salts, and (or) raubasine and (or) its salts, and (or) troxerutin and / or its salts (raubasine and troxerutin are presented in the form of the active principles and / or concentrated natural extracts as is the case with all the substances of natural origin described in any one demands). 7-Médicament selon la revendication I,caractérisé en ce qu'il contient d'une part:du ginseng et (ou) ses extraits et (ou) un ou plusieurs de ses principes actifs,et (ou) de l'éleutbérococcus et (ou) ses extraits et (ou) un ou plusieurs de ses principes,et d'autre part du ginko biloba et (ou) ses extraits et (ou) un ou plusieurs de ses principes actifs. 7-medicament according to claim I, characterized in that it contains on the one hand: ginseng and (or) its extracts and (or) one or more of its active principles, and (or) eleutbérococcus and ( or) its extracts and / or one or more of its principles, and on the other hand of ginko biloba and / or its extracts and / or one or more of its active principles. conque des revendications précédentes  conch of the preceding claims contient une quantité efficace du médicament selon lune guel contains an effective amount of the drug according to the moon 8~CompositiOn pharmaceutique caractérisée en ce quselle  8 ~ Pharmaceutical composition characterized in that
FR8509566A 1985-06-24 1985-06-24 Pharmaceutical compositions for vasculotropic and antisclerotic use Pending FR2583640A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR8509566A FR2583640A1 (en) 1985-06-24 1985-06-24 Pharmaceutical compositions for vasculotropic and antisclerotic use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8509566A FR2583640A1 (en) 1985-06-24 1985-06-24 Pharmaceutical compositions for vasculotropic and antisclerotic use

Publications (1)

Publication Number Publication Date
FR2583640A1 true FR2583640A1 (en) 1986-12-26

Family

ID=9320588

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8509566A Pending FR2583640A1 (en) 1985-06-24 1985-06-24 Pharmaceutical compositions for vasculotropic and antisclerotic use

Country Status (1)

Country Link
FR (1) FR2583640A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2602144A1 (en) * 1986-08-01 1988-02-05 Schupmann Claudia Medicaments against nausea and vomitting
FR2613223A1 (en) * 1987-04-03 1988-10-07 Biogalenique Laboratoires GALENIC FORM PRESENTING IN THE FORM OF WATER-SOLUBLE GRAINS, PARTICULARLY BASED ON A DRY GINKGO BILOBA EXTRACT, AND ITS PREPARATION METHOD
EP0293563A1 (en) * 1987-03-09 1988-12-07 OXO-Chemie GmbH Combined preparation, especially against inflammatory processes
DE3802895A1 (en) * 1988-02-01 1989-08-10 Koeltringer Peter Combination product for the treatment of disorders and injuries of nerve cells and nerve fibres
US5262162A (en) * 1991-09-06 1993-11-16 Merz & Co. Gmbh & Co. Cerebral-activating extract
EP0692250A2 (en) * 1994-07-12 1996-01-17 INDENA S.p.A. Formulations containing esculoside and the use thereof in the pharmaceutical and cosmetic fields
WO2000025764A2 (en) * 1998-10-30 2000-05-11 Merck Patent Gmbh Compositions for the treatment and prevention of cardiovascular diseases
WO2001043757A2 (en) * 1999-12-17 2001-06-21 Pharmaton S.A. Composition comprising ingredients of panax ginseng and ginko biloba
FR2851466A1 (en) * 2003-02-25 2004-08-27 Rocher Yves Biolog Vegetale Cosmetic use of inositol for improvement of oxygenation and metabolism of tissue and cutaneous cells
DE10352602A1 (en) * 2003-11-11 2005-06-02 Rovi Gmbh & Co. Kosmetische Rohstoffe Kg Cosmetic or therapeutic combination preparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5159M (en) * 1966-01-05 1967-06-12

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5159M (en) * 1966-01-05 1967-06-12

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ROTE LISTE, 1963, Editio Cantor, Aulendorf/W}rtt, DE; *
ROTE LISTE, 1965, Editio Cantor, Aulendorf/W}rtt, DE; *
ROTE LISTE, 1967, Editio Cantor, Aulendorf/W}rtt, DE; *
UNLISTED DRUGS, vol. 19, no. 12, décembre 1967, Chatham, New Jersey, US; *
UNLISTED DRUGS, vol. 23, no. 7, juillet 1971, Chatham, New Jersey, US; *
UNLISTED DRUGS, vol. 25, no. 2, février 1973, Chatham, New Jersey, US; *
UNLISTED DRUGS, vol. 25, no. 7, juillet 1973, Chatham, New Jersey, US; *
UNLISTED DRUGS, vol. 31, no. 3, mars 1979, Chatham, New Jersey, US; *
UNLISTED DRUGS, vol. 33, no. 8, août 1981, Chatham, New Jersey, US; *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2602144A1 (en) * 1986-08-01 1988-02-05 Schupmann Claudia Medicaments against nausea and vomitting
EP0293563A1 (en) * 1987-03-09 1988-12-07 OXO-Chemie GmbH Combined preparation, especially against inflammatory processes
FR2613223A1 (en) * 1987-04-03 1988-10-07 Biogalenique Laboratoires GALENIC FORM PRESENTING IN THE FORM OF WATER-SOLUBLE GRAINS, PARTICULARLY BASED ON A DRY GINKGO BILOBA EXTRACT, AND ITS PREPARATION METHOD
EP0290299A1 (en) * 1987-04-03 1988-11-09 Pierre Fabre Medicament Galenic formulation based on dry extracts of plants
DE3802895A1 (en) * 1988-02-01 1989-08-10 Koeltringer Peter Combination product for the treatment of disorders and injuries of nerve cells and nerve fibres
US5262162A (en) * 1991-09-06 1993-11-16 Merz & Co. Gmbh & Co. Cerebral-activating extract
EP0692250A2 (en) * 1994-07-12 1996-01-17 INDENA S.p.A. Formulations containing esculoside and the use thereof in the pharmaceutical and cosmetic fields
EP0692250A3 (en) * 1994-07-12 1996-10-23 Indena Spa Formulations containing esculoside and the use thereof in the pharmaceutical and cosmetic fields
WO2000025764A2 (en) * 1998-10-30 2000-05-11 Merck Patent Gmbh Compositions for the treatment and prevention of cardiovascular diseases
WO2000025764A3 (en) * 1998-10-30 2000-07-13 Merck Patent Gmbh Compositions for the treatment and prevention of cardiovascular diseases
WO2001043757A2 (en) * 1999-12-17 2001-06-21 Pharmaton S.A. Composition comprising ingredients of panax ginseng and ginko biloba
WO2001043757A3 (en) * 1999-12-17 2002-05-02 Pharmaton Sa Composition comprising ingredients of panax ginseng and ginko biloba
FR2851466A1 (en) * 2003-02-25 2004-08-27 Rocher Yves Biolog Vegetale Cosmetic use of inositol for improvement of oxygenation and metabolism of tissue and cutaneous cells
WO2004075821A2 (en) * 2003-02-25 2004-09-10 Laboratoires De Biologie Vegetale Yves Rocher Cosmetic use of inositol
WO2004075821A3 (en) * 2003-02-25 2004-10-21 Rocher Yves Biolog Vegetale Cosmetic use of inositol
DE10352602A1 (en) * 2003-11-11 2005-06-02 Rovi Gmbh & Co. Kosmetische Rohstoffe Kg Cosmetic or therapeutic combination preparation

Similar Documents

Publication Publication Date Title
US5376371A (en) Compositions for treating fat deposits in humans
US7740831B2 (en) Compositions for potentiating glutathione
US7063861B2 (en) Bioavailable composition of natural and synthetic HCA
KR20080104600A (en) Composition for treatment of ischemic heart disease, facilitation of blood circulation and angiogenesis
US20070189997A1 (en) Skin-whitening agent containing polyphenol compound
FR2583640A1 (en) Pharmaceutical compositions for vasculotropic and antisclerotic use
FR2802414A1 (en) Compositions containing raffinose or stachyose together with a saponin or arginine, have anti-allergic and anti-inflammatory activity, for the treatment of asthma, eczema, arthroses, and the like
JP6043145B2 (en) Skin external composition for body odor control
EP1013278A1 (en) The extract of pine needle and the use thereof
EP1811953B1 (en) Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics
JPH1160496A (en) Medicine for enhancing hyaluronic acid-producing ability
JP2004352658A (en) External preparation for skin
FR2787711A1 (en) COSMETIC COMPOSITION WITH DEPIGMENTING ACTIVITY AND ITS USE
WO2021060091A1 (en) Rutin compositions
US8329228B2 (en) Special extract and use thereof for inhibiting the degradation of cyclic guanosine monophosphate (cGMP)
EP1317239B1 (en) Synergetic combinations based on plants for treating hair loss
WO2009101301A2 (en) Use of a poppy petal extract for skin nutrition
WO2003000208A1 (en) Topical composition comprising a cytotoxic product
EP2142202B1 (en) Cleome spinosa extract used in pharmaceutical preparations and cosmetic compositions
EP4344556A1 (en) Composition comprising hydrangenol as active ingredient for improving hair or scalp condition
US20230111153A1 (en) Compositions derived from salvia hispanica seeds
WO2004089390A2 (en) Use of quinquina for the preparation of a medicament stimulating angiogenesis
JP2002128655A (en) Skin-bleaching cosmetic
KR20130141420A (en) Composition for treatment of ischemic heart disease, facilitation of blood circulation and angiogenesis
DE102009005201A1 (en) Use of polyphenol-containing plant extracts for the treatment of obesity and type 2 diabetes mellitus